Bristol-Myers Squibb Co
BMY54.670USD
-0.040-0.07%
Cierre 12/26, 16:00（ET）Cotizaciones retrasadas 15 min
111.31BCap. mercado
18.40P/E TTM
Más Datos de Bristol-Myers Squibb Co Compañía
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Información de Bristol-Myers Squibb Co
Símbolo de cotizaciónBMY
Nombre de la empresaBristol-Myers Squibb Co
Fecha de salida a bolsaMar 17, 1980
Director ejecutivoBoerner (Christopher S)
Número de empleados34100
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 17
DirecciónRoute 206 And Province Line Road
CiudadPRINCETON
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal08543
Teléfono16092524621
Sitio Webhttps://www.bms.com
Símbolo de cotizaciónBMY
Fecha de salida a bolsaMar 17, 1980
Director ejecutivoBoerner (Christopher S)
Ejecutivos de Bristol-Myers Squibb Co
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
63.90K
+1.88%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
19.77K
+18.37%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
11.07K
+25.18%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Dr. Deepak L. Bhatt, M.D.
Dr. Deepak L. Bhatt, M.D.
Independent Director
Independent Director
--
--
Mr. Phil Holzer
Mr. Phil Holzer
Senior Vice President, Controller
Senior Vice President, Controller
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
63.90K
+1.88%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
19.77K
+18.37%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
11.07K
+25.18%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Eliquis
3.68B
30.00%
Opdivo
2.59B
21.09%
Orencia
963.00M
7.85%
Revlimid
838.00M
6.83%
Yervoy
728.00M
5.93%
Otro
3.47B
28.29%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
8.52B
69.44%
International
3.48B
28.37%
other
270.00M
2.20%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Eliquis
3.68B
30.00%
Opdivo
2.59B
21.09%
Orencia
963.00M
7.85%
Revlimid
838.00M
6.83%
Yervoy
728.00M
5.93%
Otro
3.47B
28.29%
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
4.98%
State Street Investment Management (US)
4.74%
Charles Schwab Investment Management, Inc.
3.59%
JP Morgan Asset Management
2.90%
Otro
74.21%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
4.98%
State Street Investment Management (US)
4.74%
Charles Schwab Investment Management, Inc.
3.59%
JP Morgan Asset Management
2.90%
Otro
74.21%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
44.02%
Investment Advisor/Hedge Fund
25.70%
Research Firm
2.97%
Pension Fund
2.51%
Hedge Fund
2.51%
Bank and Trust
2.22%
Sovereign Wealth Fund
1.74%
Insurance Company
0.19%
Family Office
0.06%
Otro
18.08%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
3973
1.68B
84.73%
-171.91K
2025Q3
4147
1.68B
85.10%
-5.79M
2025Q2
4212
1.69B
83.90%
+15.56M
2025Q1
4284
1.67B
82.20%
-238.41K
2024Q4
4280
1.64B
80.20%
+45.34M
2024Q3
4106
1.59B
79.76%
+6.69M
2024Q2
4097
1.58B
82.24%
-51.64M
2024Q1
4107
1.64B
80.22%
+12.13M
2023Q4
4104
1.60B
80.80%
-21.68M
2023Q3
4025
1.62B
80.17%
-24.04M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
193.94M
9.53%
+3.47M
+1.82%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
99.37M
4.88%
+1.60M
+1.64%
Jun 30, 2025
State Street Investment Management (US)
94.74M
4.65%
-94.48K
-0.10%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
70.80M
3.48%
+10.20M
+16.82%
Jun 30, 2025
JP Morgan Asset Management
67.41M
3.31%
-2.47M
-3.54%
Jun 30, 2025
Geode Capital Management, L.L.C.
46.18M
2.27%
+723.46K
+1.59%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
33.57M
1.65%
-1.60M
-4.55%
Jun 30, 2025
Capital International Investors
66.16M
3.25%
-303.34K
-0.46%
Jun 30, 2025
Columbia Threadneedle Investments (US)
29.38M
1.44%
+350.53K
+1.21%
Jun 30, 2025
PRIMECAP Management Company
22.94M
1.13%
-25.98K
-0.11%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: vie., 5 de dic
Actualizado: vie., 5 de dic
Nombre
Proporción
VanEck Pharmaceutical ETF
9.15%
First Trust NASDAQ Pharmaceuticals ETF
7.58%
Franklin US Dividend Booster Index ETF
5.08%
WBI Power Factor High Dividend ETF
4.88%
VanEck Morningstar Wide Moat Value ETF
4.34%
iShares U.S. Pharmaceuticals ETF
4.31%
Schwab U.S. Dividend Equity ETF
3.74%
ETC 6 Meridian Hedged Equity Index Option ETF
3.68%
ETC 6 Meridian Mega Cap Equity ETF
3.58%
Brookstone Value Stock ETF
3.48%
Ver más
VanEck Pharmaceutical ETF
Proporción9.15%
First Trust NASDAQ Pharmaceuticals ETF
Proporción7.58%
Franklin US Dividend Booster Index ETF
Proporción5.08%
WBI Power Factor High Dividend ETF
Proporción4.88%
VanEck Morningstar Wide Moat Value ETF
Proporción4.34%
iShares U.S. Pharmaceuticals ETF
Proporción4.31%
Schwab U.S. Dividend Equity ETF
Proporción3.74%
ETC 6 Meridian Hedged Equity Index Option ETF
Proporción3.68%
ETC 6 Meridian Mega Cap Equity ETF
Proporción3.58%
Brookstone Value Stock ETF
Proporción3.48%
Dividendos
Un total de
22.71B
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Dec 10, 2025
BMY.NB Interim Cash Dividend of gross USD 0.63 paid on Feb 02, 2026 going ex on Jan 02, 2026 with reinvestment option
Jan 02, 2026
Feb 02, 2026
Jan 02, 2026
Sep 17, 2025
BMY.NB Final Cash Dividend of gross USD 0.62 paid on Nov 03, 2025 going ex on Oct 03, 2025 with reinvestment option
Oct 03, 2025
Nov 03, 2025
Oct 03, 2025
Jun 17, 2025
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Aug 01, 2025 going ex on Jul 03, 2025 with reinvestment option
Jul 03, 2025
Aug 01, 2025
Jul 03, 2025
Mar 03, 2025
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on May 01, 2025 going ex on Apr 04, 2025 with reinvestment option
Apr 04, 2025
May 01, 2025
Apr 04, 2025
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
Ver más
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Bristol-Myers Squibb Co?
Los cinco principales accionistas de Bristol-Myers Squibb Co son:
The Vanguard Group, Inc. posee 193.94M acciones, lo que representa el 9.53% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 99.37M acciones, lo que representa el 4.88% del total de acciones.
State Street Investment Management (US) posee 94.74M acciones, lo que representa el 4.65% del total de acciones.
Charles Schwab Investment Management, Inc. posee 70.80M acciones, lo que representa el 3.48% del total de acciones.
JP Morgan Asset Management posee 67.41M acciones, lo que representa el 3.31% del total de acciones.
The Vanguard Group, Inc. posee 193.94M acciones, lo que representa el 9.53% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 99.37M acciones, lo que representa el 4.88% del total de acciones.
State Street Investment Management (US) posee 94.74M acciones, lo que representa el 4.65% del total de acciones.
Charles Schwab Investment Management, Inc. posee 70.80M acciones, lo que representa el 3.48% del total de acciones.
JP Morgan Asset Management posee 67.41M acciones, lo que representa el 3.31% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Bristol-Myers Squibb Co?
Los tres principales tipos de accionista de Bristol-Myers Squibb Co son:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
¿Cuántas instituciones poseen acciones de Bristol-Myers Squibb Co (BMY)?
A fecha de 2025Q4, 3973 instituciones poseen acciones de Bristol-Myers Squibb Co, con un valor de mercado combinado de aproximadamente 1.68B, lo que representa el 84.73% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -0.37%.
¿Cuál es la mayor fuente de ganancias de Bristol-Myers Squibb Co?
El FY2025Q2, el segmento empresarial Eliquis generó la ganancia más alta para Bristol-Myers Squibb Co, ascendiendo a 3.68B y representando el 30.00% de la ganancia total.
